Patents by Inventor Alessia Petrocchi

Alessia Petrocchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZABICYCLIC SHP2 INHIBITORS
    Publication number: 20240109900
    Abstract: The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
    Type: Application
    Filed: February 8, 2022
    Publication date: April 4, 2024
    Inventors: Alina CIAMMAICHELLA, Romano DI FABIO, Federica FERRIGNO, Paola FEZZARDI, Christian MONTALBETTI, Alessia PETROCCHI, Nicola RELITTI, Ilaria ROSSETTI, Alessio SFERRAZZA, Esther TORRENTE, Luca FERRANTE, Alessandro GRILLO
  • GLS1 inhibitors for treating disease
    Patent number: 11713313
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 1, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • SHP2 INHIBITORS
    Publication number: 20220289753
    Abstract: The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
    Type: Application
    Filed: August 7, 2020
    Publication date: September 15, 2022
    Applicants: IRBM S.P.A., C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Alina CIAMMAICHELLA, Federica FERRIGNO, Jesus Maria ONTORIA ONTORIA, Alessia PETROCCHI, Simona PONZI, Ilaria ROSSETTI, Alessio SFERRAZZA, Esther TORRENTE
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11173145
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 16, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Jason Cross, Michelle Han, Michael Soth, Timothy McAfoos, Martin Tremblay
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11046649
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Timothy McAfoos, Jason Bryant Cross, Michael J. Soth
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 11001594
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20210122744
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 1, 2020
    Publication date: April 29, 2021
    Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
  • GLS1 inhibitors for treating disease
    Patent number: 10738043
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 11, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE
    Publication number: 20200024236
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 23, 2020
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Timothy MCAFOOS, Jason Bryant CROSS, Michael J. SOTH
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE
    Publication number: 20190365718
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Jason CROSS, Michele HAN, Michael SOTH, Timothy MCAFOOS, Martin TREMBLAY
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20190270753
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 5, 2019
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Alessia PETROCCHI, Christopher L. CARROLL, Joe MARSZALEK, Barbara CZAKO, Ryan JOHNSON, Jay THEROFF
  • HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE
    Publication number: 20190135793
    Abstract: The present invention relates to compounds and methods useful as inhibitors of KDM5 for the treatment or prevention of cancer.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 9, 2019
    Inventors: Alessia PETROCCHI, Maria Emilia DI FRANCESCO, Philip JONES, Richard Thomas LEWIS, Naphtali REYNA, Matthew HAMILTON, Michelle HAN
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 10208059
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 19, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190031651
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 31, 2019
    Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
  • GLS1 inhibitors for treating disease
    Patent number: 10125128
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 13, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
    Patent number: 9670196
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring A, and the subscripts n1, n2, and r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas A. Miller, Alessia Petrocchi, Eric T. Romeo, Dilrukshi Vitharana, Solomon D. Kattar, Alan B. Northrup, Michael D. Altman, Neville J. Anthony
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20170121342
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: October 4, 2016
    Publication date: May 4, 2017
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20170001996
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 5, 2017
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS
    Publication number: 20160326156
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring A, and the subscripts n1, n2, and r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Application
    Filed: December 18, 2014
    Publication date: November 10, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Thomas A. Miller, Alessia Petrocchi, Eric T. Romeo, Dilrukshi Vitharana, Solomon D. Kattar, Alan B. Northrup, Michael D. Altman, Neville J. Anthony
  • Imidazolyl analogs as syk inhibitors
    Patent number: 9487504
    Abstract: The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: November 8, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Jongwon Lim, Michael H. Reutershan, John Michael Ellis, Kaleen Konrad Childers, Anthony Donofrio, Michael D. Altman, Andrew M. Haidle, Anna Zabierek, Matthew Christopher, Jonathan Grimm, Jason Burch, Maria Emilia Di Francesco, Alessia Petrocchi, Christian Beaulieu, Vouy Linh Truong, Alan B. Northrup, Marc Blouin